Flamma receives 2024 Panda d’Oro Award from CICC
The Flamma Group, a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry, and CDMO of New Chemical Entities (NCEs) and late-stage intermediates, is investing $200 million over the next three years as the company continues to respond to market demand.
The Flamma Group, a global company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry and a Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates, will acquire a third API manufacturing site in Italy as of April 2022.
Italian contract development and manufacturing organization Flamma SpA has spent the past three years boosting its pharmaceutical ingredient business in China, Italy and the U.S. Now, it's breaking ground at a massive R&D facility on the company's home turf.
Flamma scores the maximum CMO Leadership Awards for the 2nd straight year
Flamma celebrates Grand Opening of $20M facility in China featuring cGMP workshop and R&D center
FLAMMA Opens New cGMP Kilo Lab Suite in Italy and plans construction of new R&D building
FLAMMA announces the successful CFDA inspection of Flamma Honkai
FLAMMA sweeps 2018 CMO Leadership Awards for the 3rd year in a row